Working towards more effective tuberculosis (TB) vaccinations, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with “kill switches” that may be activated to stop the bacteria after they elicit an immune response. Two preclinical research addresses the difficulty of designing bacteria that are safe for use in controlled human infection trials or.
